% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Fasching:310360,
      author       = {P. A. Fasching and C. Brucker and T. Decker and A. Engel
                      and T. Göhler and C. Jackisch and J. Janssen and A. Köhler
                      and K. Lüdtke-Heckenkamp and D. Lüftner and F. Marmé and
                      M. van Mackelenbergh and B. Rautenberg and M. Schmidt and R.
                      Weide and P. Wimberger$^*$ and E. Kisseleff and C. Pfister
                      and C. Quiering and C. Roos and A. Wöckel},
      title        = {{R}eal-world progression-free survival and overall survival
                      in patients with {HR}+/{HER}2- advanced breast cancer
                      treated in first-line with ribociclib, endocrine monotherapy
                      or chemotherapy: {R}esults from the observational {RIBANNA}
                      study.},
      journal      = {International journal of cancer},
      volume       = {nn},
      issn         = {0020-7136},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2026-00556},
      pages        = {nn},
      year         = {2026},
      note         = {#NCTZFB9# / epub},
      abstract     = {Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i)
                      combined with endocrine therapy are the preferred choice for
                      first-line treatment of patients with HR+/HER2- locally
                      advanced/metastatic breast cancer (aBC). The CDK4/6i
                      ribociclib in combination with an aromatase inhibitor (AI)
                      or fulvestrant (FUL) has demonstrated significant
                      progression-free survival (PFS) and overall survival (OS)
                      benefits for pre- and postmenopausal aBC patients who were
                      enrolled in the three pivotal MONALEESA trials. Following
                      the initial approval of ribociclib in 2017, the
                      non-interventional RIBANNA study was initiated to evaluate
                      the effectiveness and safety of ribociclib plus AI/FUL
                      therapy among patients with aBC in a real-world setting. Two
                      additional treatment cohorts (endocrine monotherapy [ET] and
                      chemotherapy [CT]) were included to extend the knowledge
                      about current aBC treatments. A total of 2567 patients were
                      enrolled in 279 study centers, of whom 1852 were treated
                      with ribociclib+AI/FUL, 183 were treated with ET, and 139
                      were treated with CT, who were available for effectiveness
                      analyses. Median PFS (mPFS) and median OS (mOS) on
                      first-line treatment with ribociclib+AI/FUL were 35.0 and
                      76.0 months, respectively. Adjustment for differences in
                      demographic and baseline characteristics resulted in a
                      longer mPFS on ribociclib+AI/FUL (34.7 months) compared to
                      ET (26.4 months) or CT (19.2 months). Adverse events (AEs)
                      on ribociclib were consistent with those seen in the pivotal
                      trials, and no new safety signals were observed. The RIBANNA
                      study confirmed the PFS and OS benefit seen in the MONALEESA
                      trials. Together with the safety data, this large real-world
                      dataset supports the favorable risk/benefit profile of
                      ribociclib in large scale patient populations.},
      keywords     = {CDK4/6 inhibitors (Other) / metastatic breast cancer
                      (Other) / observational study (Other) / overall survival
                      (Other) / ribociclib (Other)},
      cin          = {DD04},
      ddc          = {610},
      cid          = {I:(DE-He78)DD04-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41792052},
      doi          = {10.1002/ijc.70397},
      url          = {https://inrepo02.dkfz.de/record/310360},
}